NeuroVive reports promising progress in its clinical project for genetic mitochondrial diseases, KL1333
Lund, Sweden, 11 December 2017 – NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) and Yungjin Pharm today announced that the phase I clinical study in Korea within the companies’ joint project KL1333, an investigational treatment for genetic mitochondrial disorders, including MELAS (Mitochondrial Myopathy, Encephalopahty, Lactic Acidosis and Stroke-like episodes), is proceeding according to plan.The first part of the study has been successful. The pharmacokinetic data was in line with expectations and no adverse safety signals were detected. The study’s remaining higher